Liver Transplantation for Non-Resectable Intrahepatic Cholangiocarcinoma: a Prospective Exploratory Trial (TESLA Trial)

Inclusion Criteria:

• Histologically verified diagnosis of Intrahepatic Cholangiocarcinoma (iCCA)
• First time iCCA or liver only recurrence after previous liver resection for iCCA
• Disease deemed not eligible for liver resection based on tumor location or underlyingliver dysfunction
• No vascular invasion, extrahepatic disease, or lymph node involvement detected onimaging
• No signs of extrahepatic metastatic disease according to positron emission computedtomography (PET-CT) scan
• Patient must be accepted for transplantation before progressive disease onchemotherapy.
• Twelve months or more time span from the diagnosis of iCCA and date of being listedfor liver transplantation
• No signs of extrahepatic metastatic disease according to CT or magnetic resonance (MR)scan within 4 weeks prior to the faculty meeting at the transplant unit
• At least 18 years of age
• Good performance status, Eastern Cooperative Oncology Group (ECOG) 0 or 1
• Signed informed consent and expected cooperation of the patients for the treatment andfollow up
• Received at least 6 months of chemotherapy or locoregional therapy

Exclusion Criteria:

• Major vascular involvement of the tumor
• Perforation of the visceral peritoneum
• Weight loss >15% the last 6 months
• Patient BMI > 30
• Other malignancies, except curatively treated more than 5 years ago without relapse
• Known history of human immunodeficiency virus (HIV) infection
• Prior history of solid organ or bone marrow transplantation
• Substance abuse, medical, psychological, or social conditions that may interfere withthe patient's participation in the study or evaluation of the study results
• Known hypersensitivity to rapamycin
• Prior extrahepatic metastatic disease
• Women who are pregnant or breast feeding
• Any reason why, in the opinion of the investigator, the patient should not participate